CA125 is commonly used as a biomarker to monitor ovarian cancer disease progression and relapse as it is highly expressed in ovarian carcinomas yet minimally expressed in normal ovarian tissues [32,33,34]. This evidence concerns the gene MUC16 and ovarian cancer.